key: cord-0790442-2tr7w0mt
authors: Alfano, Gaetano; Fontana, Francesco; Mori, Giacomo; Giovanella, Silvia; Giaroni, Francesco; Ligabue, Giulia; Guaraldi, Giovanni; Magistroni, Riccardo; Cappelli, Gianni
title: Seroconversion after COVID-19 vaccine in a patient on dialysis on immune suppressants
date: 2021-03-18
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab065
sha: 150bbc4dd1bf2f0e809dd9fcacd9a51da4f68032
doc_id: 790442
cord_uid: 2tr7w0mt

nan

We report the case of seroconversion to COVID-19 vaccine in a patient on maintenance peritoneal dialysis.

A 53-year-old Caucasian woman started peritoneal dialysis in September 2020, after the failure of a cadaveric kidney transplant performed in 1996. A preserved residual renal function prompted the prescription of an incremental automatic peritoneal dialysis (APD) 4-days-per-week treatment (10 liters over 7 hours). The etiology of ESRD was unknown and her medical history included multiple skin cancers, uterine fibroid, recurrent urinary tract infections and pancreatic serous cystadenoma.

Anti-rejection immunosuppressive therapy was based on cyclosporin (CyA), steroid and azathioprine until November 2020. Afterwards, the therapy was reduced to cyclosporin (50 mg/die) and steroid (4 mg every other day). As a result, a vast campaign of sensibilization has been conducted to prioritize COVID-19 vaccination in CKD patients receiving dialysis treatment. 7, 8 This case shows that COVID-19 vaccine using RNA platform 9 is effective in inducing seroconversion in a dialysis patient with a long-term maintenance immunosuppressive therapy. The titer of her neutralizing antibodies, albeit lower than that detected in local health workers (generally >200 UI/ml using CLIA), confirms IgG seroconversion against SARS-CoV-2 spike protein. This result enforces the efforts of the medical community to prioritize vaccination in patients receiving dialysis. Considering that successful vaccinations have been reported against other infectious diseases in dialysis patients, a proactive COVID-19 pro-vaccination approach is needed to face the medical nihilism of some national health policies, as well as, to offer health equity to this vulnerable population.

The attenuate response to COVID-19 vaccine detected in this patient should be a stimulus to collect post-vaccination data on COVID-19 vaccine efficacy in terms of disease severity and infectivity.

There is also an urgent need to evaluate vaccine-induced protection in dialysis patients with an impaired immune system due to previous immunosuppression therapies to treat glomerulonephritis or avoid graft rejection. The answers to questions concerning quantitative thresholds of antibody titers to achieve adequate protection and the durability of the immune response are still unknown and will require well-designed studies to be addressed. In the meantime, further efforts should be made to offer the best-immunized protocol to maximize the protection of our patients.

Factors associated with COVID-19-related death using OpenSAFELY

Coronavirus disease 2019 in chronic kidney disease

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

Risks prediction of COVID-19 incidence and mortality in a large multi-national haemodialysis cohort: Implications for management of the pandemic in outpatient haemodialysis settings

SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience

At least 156 reasons to prioritise COVID-19 vaccination in patients receiving in-centre haemodialysis

The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine